SEC Comment Letter 0000000000-25-002417 to Aclaris Therapeutics, Inc. (ACRS) (CIK 0001557746) (ACRS)
Aclaris Therapeutics, Inc. (ACRS) (CIK 0001557746)
Date: March 4, 2025 · CIK: 0001557746 · Accession: 0000000000-25-002417
AI Filing Summary & Sentiment
File numbers found in text: 333-285370
Letter
March 4, 2025 Neal Walker Chief Executive Officer Aclaris Therapeutics, Inc. 701 Lee Road, Suite 103 Wayne, PA 19087 Re:Aclaris Therapeutics, Inc. Registration Statement on Form S-3 Filed February 27, 2025 File No. 333-285370 Dear Neal Walker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:David Brinton
Show Raw Text
March 4, 2025
Neal Walker
Chief Executive Officer
Aclaris Therapeutics, Inc.
701 Lee Road, Suite 103
Wayne, PA 19087
Re:Aclaris Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 27, 2025
File No. 333-285370
Dear Neal Walker:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:David Brinton